[Prediction of adverse drug reactions based on genomic information].
Sawada
Jun-ichi
J
Division of Biochemistry and Immunochemistry, National Institute of Health Sciences.
Saito
Yoshiro
Y
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000378:metabolism; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000378:metabolism; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000378:metabolism; D001191:Arylamine N-Acetyltransferase / Q000235:genetics; D044466:Asian People; D001379:Azathioprine / Q000009:adverse effects* / Q000378:metabolism; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism; D003564:Cytidine Deaminase / Q000235:genetics; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000378:metabolism; D005544:Forecasting; D014453:Glucuronosyltransferase / Q000235:genetics*; D006801:Humans; D000077146:Irinotecan; D015122:Mercaptopurine / Q000009:adverse effects* / Q000378:metabolism; D008780:Methyltransferases / Q000235:genetics*; D011110:Polymorphism, Genetic; D011355:Prodrugs / Q000009:adverse effects* / Q000378:metabolism; D013420:Sulfamethoxazole / Q000009:adverse effects / Q000378:metabolism; D000093542:Gemcitabine; D000099148:UGT1A1 Enzyme
D000890:Anti-Infective Agents; D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D001191:Arylamine N-Acetyltransferase; D001379:Azathioprine; D002166:Camptothecin; D003564:Cytidine Deaminase; D003841:Deoxycytidine; D014453:Glucuronosyltransferase; D000077146:Irinotecan; D015122:Mercaptopurine; D008780:Methyltransferases; D011355:Prodrugs; D013420:Sulfamethoxazole; D000093542:Gemcitabine; D000099148:UGT1A1 Enzyme; C022745:thiopurine methyltransferase; C478900:NAT2 protein, human